Executive Advisor (Global Market Access)
Cheryl has extensive cross-functional experience in pricing/reimbursement, commercial strategy, market insights, and business development as both a consultant and as an in-house director at AstraZeneca.
From 2014-2018, Cheryl led Evidera’s Global Market Access Consulting practice, where she aided clients in developing evidence and value strategies to optimize price, HTA outcomes, and market access for novel pharmaceuticals and innovative medical products. She led projects including comprehensive global payer landscape projects to inform phase-gate investment decisions, rapid payer assessments to inform in-licensing decisions, payer negotiation strategy workshops, value evidence generation strategies, and value communication strategies.
Prior to Evidera, Cheryl was a Director within AstraZeneca’s New Opportunities iMed, where she was engaged in developing strategies to expand AZ’s business beyond its core therapeutic focus, to identify and evaluate in-licensing opportunities of interest within those strategies, and to support asset repurposing as a new product planning leader.
Prior to AstraZeneca, Cheryl was a consulting leader at IQVIA, Decision Resources Group, and the Kerdan Group. Within these consultancies, Cheryl led client engagements that integrated in-depth primary research across patient, physician, and payer stakeholders with secondary research and strategic frameworks to aid clients in developing portfolio and therapeutic growth strategies, commercial brand planning, in-licensing assessments, phase-gate transition decisions, and forecasting.
Cheryl holds a BSFS in international economics from Georgetown University.